{"id":"angiotensin-ii-type-1-receptor-blocker","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"3-5","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"1-3","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ARBs selectively antagonize the AT1 receptor, which is responsible for the vasoconstrictive and aldosterone-releasing effects of angiotensin II. By blocking this receptor, ARBs cause vasodilation, reduce peripheral vascular resistance, and lower blood pressure. They also reduce sodium reabsorption in the kidneys and have cardioprotective effects in heart failure and post-myocardial infarction patients.","oneSentence":"Angiotensin II Type 1 Receptor Blockers (ARBs) block the angiotensin II receptor on blood vessel walls, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:28.709Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT02085265","phase":"PHASE2","title":"Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2014-03","conditions":"Alzheimer's Disease","enrollment":23},{"nctId":"NCT06501651","phase":"PHASE4","title":"Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2024-08-01","conditions":"Essential Hypertension, Type 2 Diabetes, Nephropathy","enrollment":297},{"nctId":"NCT03552575","phase":"PHASE3","title":"The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-07-01","conditions":"Heart Failure","enrollment":93},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":"Covid19, SARS-CoV Infection","enrollment":341},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT01091961","phase":"NA","title":"Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT03066804","phase":"PHASE3","title":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-22","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2572},{"nctId":"NCT04408326","phase":"","title":"Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2020-06-01","conditions":"COVID, Acute Respiratory Distress Syndrome","enrollment":50},{"nctId":"NCT04954560","phase":"NA","title":"Effect of Losartan or Eprosartan on Fructose Hyperuricemia","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2008-01-01","conditions":"Uric Acid Concentration, Serum, Quantitative Trait Locus 7","enrollment":16},{"nctId":"NCT02709018","phase":"NA","title":"A Controlled Trial of Losartan in Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-07-16","conditions":"Posttraumatic Stress Disorder","enrollment":149},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04318418","phase":"","title":"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","status":"COMPLETED","sponsor":"Neuromed IRCCS","startDate":"2020-03-23","conditions":"COVID-19","enrollment":3400},{"nctId":"NCT04524494","phase":"","title":"Human Intestinal Amino Acid Absorption and the Role of a Local RAS","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2010-01-27","conditions":"Renin-Angiotensin Aldosterone System (RAS)","enrollment":50},{"nctId":"NCT04510623","phase":"","title":"Host Response Mediators in Coronavirus (COVID-19) Infection","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2020-03-17","conditions":"COVID-19, SARS-CoV2","enrollment":500},{"nctId":"NCT04401228","phase":"","title":"Predictive Models for Intensive Care Admission and Death of COVID-19","status":"UNKNOWN","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2020-03-01","conditions":"COVID19, Pneumonia, Viral, Inflammatory Response","enrollment":60},{"nctId":"NCT02788656","phase":"PHASE4","title":"Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2016-09","conditions":"Congestive Heart Failure","enrollment":4},{"nctId":"NCT02363725","phase":"PHASE2","title":"Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2014-12","conditions":"Acute Myocardial Infarction","enrollment":44},{"nctId":"NCT02944734","phase":"PHASE2","title":"Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2014-09","conditions":"Essential Hypertension","enrollment":392},{"nctId":"NCT00403481","phase":"PHASE4","title":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-11","conditions":"Hypertension","enrollment":192},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT01815762","phase":"NA","title":"Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients","status":"COMPLETED","sponsor":"Grigore T. Popa University of Medicine and Pharmacy","startDate":"2013-03","conditions":"Patients on Hemodialysis for More Than 3 Months","enrollment":250},{"nctId":"NCT00763893","phase":"PHASE3","title":"Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-09","conditions":"Marfan Syndrome","enrollment":303},{"nctId":"NCT00265642","phase":"PHASE3","title":"Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2006-10","conditions":"Hepatitis C, Chronic","enrollment":166},{"nctId":"NCT00126516","phase":"PHASE4","title":"Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline","status":"COMPLETED","sponsor":"Nara Medical University","startDate":"2004-05","conditions":"Brain Infarction, Hypertension","enrollment":395},{"nctId":"NCT01101503","phase":"PHASE2","title":"The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Xiang Guang-da","startDate":"2010-04","conditions":"Endothelial Dysfunction","enrollment":1000},{"nctId":"NCT00454662","phase":"PHASE4","title":"Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)","status":"COMPLETED","sponsor":"COLM Study Research Organization","startDate":"2007-04","conditions":"Hypertension, Cardiovascular Disease, Diabetes","enrollment":5141},{"nctId":"NCT00791830","phase":"PHASE3","title":"Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2009-04","conditions":"Kidney Failure, Chronic","enrollment":82},{"nctId":"NCT01670903","phase":"","title":"The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2011-05","conditions":"Aneurysm, Hypertension","enrollment":150},{"nctId":"NCT01124656","phase":"PHASE3","title":"Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00162955","phase":"PHASE4","title":"Prevention of CHOP-induced Chronic Cardiotoxicity","status":"COMPLETED","sponsor":"Osaka City University","startDate":"2004-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT01444833","phase":"NA","title":"Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker","status":"UNKNOWN","sponsor":"Slovak Academy of Sciences","startDate":"2008-10","conditions":"Hypertension","enrollment":35},{"nctId":"NCT00134160","phase":"PHASE4","title":"OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study","status":"COMPLETED","sponsor":"OSCAR Study","startDate":"2005-08","conditions":"Hypertension, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT01015937","phase":"NA","title":"Effect of Turmeric on Diabetic Nephropathy","status":"COMPLETED","sponsor":"Shaheed Faghihi Hospital","startDate":"2008-03","conditions":"Diabetic Nephropathy, Proteinuria","enrollment":50},{"nctId":"NCT00890591","phase":"PHASE4","title":"Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-08","conditions":"Essential Hypertension","enrollment":144},{"nctId":"NCT00235287","phase":"PHASE4","title":"Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease","status":"UNKNOWN","sponsor":"Herlev Hospital","startDate":"2005-09","conditions":"Kidney Failure, Chronic, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT00774904","phase":"NA","title":"Adiponectin and Insulin Resistance in Diabetic Nephropathy","status":"COMPLETED","sponsor":"Xi'an Jiaotong University","startDate":"2007-04","conditions":"Diabetic Nephropathy","enrollment":80},{"nctId":"NCT00001629","phase":"PHASE3","title":"The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1997-07","conditions":"Atherosclerosis, Heart Failure, Congestive, Hypertension","enrollment":49},{"nctId":"NCT00001628","phase":"PHASE3","title":"The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1997-07","conditions":"Atherosclerosis, Heart Failure, Congestive, Hypertension","enrollment":36},{"nctId":"NCT00572312","phase":"NA","title":"Optimalization of Nephroprotection Using Atorvastatin (Sortis)","status":"COMPLETED","sponsor":"Medical University of Gdansk","startDate":"2005-02","conditions":"Chronic Kidney Disease, Proteinuria","enrollment":""},{"nctId":"NCT00561704","phase":"NA","title":"Adiponectin in Obese Women With T2DN and Effects by RAS Blocker","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2007-04","conditions":"Obese, Type 2 Diabetes, Diabetic Nephropathy","enrollment":80},{"nctId":"NCT00361023","phase":"NA","title":"Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2006-01","conditions":"Type 2 Diabetes, Diabetic Nephropathy","enrollment":25},{"nctId":"NCT00144144","phase":"PHASE4","title":"A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Advanced-J","startDate":"2004-09","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":559,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Angiotensin Receptor Blocker, ARB"],"phase":"marketed","status":"active","brandName":"Angiotensin II Type 1 Receptor Blocker","genericName":"Angiotensin II Type 1 Receptor Blocker","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Angiotensin II Type 1 Receptor Blockers (ARBs) block the angiotensin II receptor on blood vessel walls, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}